BCRX (BioCryst Pharmaceuticals) Selling, General, & Admin. Expense: $360.7 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCRX BioCryst Pharmaceuticals Inc BCRX
67 GF Score
Price $9.29
GF Value $12.38
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Selling, General, & Admin. Expense?

BioCryst Pharmaceuticals BCRX +2.03% 67 Selling, General, & Admin. Expense is $360.7 Mil as of Mar. 2026. GuruFocus rates BCRX with a GF Score™ of 67/100 and a GF Value™ of $12.38 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. BioCryst Pharmaceuticals's selling, general, & admin. expense for the three months ended in Mar. 2026 was $94.6 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was $360.7 Mil.


BioCryst Pharmaceuticals  (NAS:BCRX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


BioCryst Pharmaceuticals Selling, General, & Admin. Expense Related Terms


BioCryst Pharmaceuticals Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals Selling, General, & Admin. Expense Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 118.82 159.37 214.07 266.35 348.65

BioCryst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.47 87.38 83.01 95.78 94.55

BCRX vs SUPN, PBH, AMLX: Selling, General, & Admin. Expense Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals Selling, General, & Admin. Expense vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Selling, General, & Admin. Expense falls into.


BCRX
67GF Score
BioCryst Pharmaceuticals Inc BCRX
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCryst Pharmaceuticals Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $360.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $360.7 Mil mean?
BioCryst Pharmaceuticals (BCRX) has a Selling, General, & Admin. Expense of $360.7 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on BioCryst Pharmaceuticals and its competitors.
Is BioCryst Pharmaceuticals' Selling, General, & Admin. Expense too high?
BioCryst Pharmaceuticals' current Selling, General, & Admin. Expense is $360.7 Mil. Overall, BioCryst Pharmaceuticals has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Selling, General, & Admin. Expense compare to SUPN and PBH?
BioCryst Pharmaceuticals' Selling, General, & Admin. Expense of $360.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on BioCryst Pharmaceuticals and its competitors. BioCryst Pharmaceuticals's current Selling, General, & Admin. Expense is $360.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.38, compared to a current price of $9.29 — trading 25% below its estimated fair value. The current Selling, General, & Admin. Expense is $360.7 Mil. BioCryst Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current Selling, General, & Admin. Expense is $360.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of $9.29 is trading 25% below its estimated GF Value™ of $12.38. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BCRX:

  • Selling, General, & Admin. Expense: $360.7 Mil
  • GF Value™: $12.38 vs. price of $9.29 (25% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:MexicoBO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
67GF Score

Get the complete analysis for BCRX

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.29
Price
$12.38
GF Value